WILSON JAMES N sold $1.1M of CORT (indirect holdings)
WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.81 ($114.48–$116.30, $1.15M total) across 3 trades on 2026-10-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh, material data that may affect short-term price dynamics for CORT.
Market read
Primary insider sale news; modest but actionable for short-term traders monitoring biotech stocks.
What to watch
The director's 10b5-1 plan suggests pre-scheduled execution, reducing negative inference.
Background
SEC Form 4 filings disclose insider transactions; a director's sale is publicly reported and can influence investor sentiment.
Ticker impact
Director Wilson James N sold 10,000 shares for $1.148M via a Form 4 filing, reducing his holdings to 1,054,543 shares.
likely downward pressure as the market prices in the insider sell
Form 4 is a primary source; a $1.1M sale by a director is material and new information.
Market effects
May raise concerns for other biotech stocks if insider selling is viewed as a sector signal.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to CORT shareholders.
Counterpoint
The sale could be a routine liquidity move unrelated to company fundamentals.
Key entities
- CompanyCorcept Therapeutics Inc.
Biopharmaceutical company developing treatments for endocrine disorders.
- IndividualWilson James N.
Director of Corcept Therapeutics who executed the sale.
